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ABSTRACT 
 
Rationale: Over the last decade many new psychostimulant analogues have appeared on the 
recreational drug market and most are derivatives of amphetamine or cathinone.  Another class 
of designer drugs is derived from the 2-aminoindan structural template.  Several members of this 
class, including the parent compound 2-aminoindan (2-AI), have been sold as designer drugs.  
Another aminoindan derivative, 5-methoxy-2-aminoindan (5-MeO-AI or MEAI), is the active 
ingredient in a product marketed online as an alcohol substitute. Methods: Here we tested 2-AI 
and its ring-substituted derivatives 5-MeO-AI, 5-methoxy-6-methyl-2-aminoindan (MMAI), and 
5,6-methylenedioxy-2-aminoindan (MDAI) for their abilities to interact with plasma membrane 
monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT).  We 
also compared the binding affinities of the aminoindans at 29 receptor and transporter binding 
sites. Results: 2-AI was a selective substrate for NET and DAT.  Ring substitution increased 
potency at SERT while reducing potency at DAT and NET.  MDAI was moderately selective for 
SERT and NET, with 10-fold weaker effects on DAT.  5-MeO-AI exhibited some selectivity for 
SERT, having 6-fold lower potency at NET and 20-fold lower potency at DAT.  MMAI was 
highly selective for SERT, with 100-fold lower potency at NET and DAT.  The aminoindans had 
relatively high affinity for α2-adrenoceptor subtypes.  2-AI had particularly high affinity for α2C 
receptors (Ki = 41 nM) and slightly lower affinity for the α2A (Ki = 134 nM) and α2B (Ki = 211 
nM) subtypes.  5-MeO-AI and MMAI also had moderate affinity for the 5-HT2B receptor.  
Conclusions: 2-AI is predicted to have (+)-amphetamine-like effects and abuse potential whereas 
the ring-substituted derivatives may produce 3,4-methylenedioxymethamphetamine (MDMA)-
like effects but with less abuse liability. 
 
Keywords: dopamine, serotonin, norepinephrine, synaptosomes, binding, analgesia, stimulant, 
MEAI 
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1.  INTRODUCTION 
 
 Although the phenomenon of designer drugs is not new, many novel controlled substance 
analogues have appeared on the recreational (i.e., non-medical) drug market over the last decade.  
New analogues are appearing at an alarming rate and the widespread availability and misuse of 
these substances is causing a significant public health problem (Baumann and Volkow 2016; 
Halberstadt 2017; Huestis et al. 2017).  Some of these substances are amphetamine derivatives, 
for example 4-fluoroamphetamine and 4-methylamphetamine (Johansen and Hansen 2012; 
Elliott and Evans 2014; Linsen et al. 2015; Solis et al. 2017).  Other substances are derived from 
cathinone (2-amino-1-phenylpropan-1-one), the β-keto analogue of amphetamine, which occurs 
naturally in the leaves of the Khat plant Catha edulis.  Amphetamine and cathinone derivatives 
act as substrates for plasma membrane monoamine transporters and promote the non-exocytotic 
release of norepinephrine (NE), dopamine (DA), and serotonin (5-HT) (Rothman et al. 2001; 
Baumann et al. 2012; Cozzi et al. 2013; Hutsell et al. 2016; Eshleman et al. 2017).  The effects 
and abuse potential of monoamine releasers vary depending on their selectivity for NE, DA, and 
5-HT transporters (NET/SLC6A2, DAT/SLC6A3, and SERT/SLC6A4, respectively).  
Substances that are relatively selective for NET and DAT, such as (+)-amphetamine and (+)-
methamphetamine, act as psychostimulants, whereas 3,4-methylenedioxymethamphetamine 
(MDMA, “Ecstasy”) is nonselective for NET, DAT and SERT and is thought to produce 
“entactogenic” effects via 5-HT release (Liechti et al. 2000; Farre et al. 2007; Tancer and 
Johanson 2007).  The abuse liability of monoamine-releasing drugs is correlated with their 
capacity to release NE and DA (Rothman et al. 2001).  Conversely, non-selective or 5-HT-
selective releasers have reduced abuse-potential, as evidenced by self-administration and 
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intracranial self-stimulation (ICSS) measures (Wee et al. 2005; Bauer et al. 2013; Schindler et al. 
2016).   
 In addition to the cathinone derivatives, another class of designer drugs is derived from 
the 2-aminoindan structural template (see Figure 1).  These substances can be viewed as cyclic 
analogues of amphetamines.  The parent compound of this structural class, 2-aminoindan (2-AI, 
Su-8629), was likely first synthesized by Benedikt (1893) in low yield from 2-indanone via 
reduction of the oxime derivative.  In terms of its human psychopharmacology, 2-AI reportedly 
produces mild stimulant effects, with a p.o. dose range of 50-100 mg (Anonymous 2017).  2-AI 
has been available in Europe as a designer drug (EMCDDA 2007; Brandt et al. 2013; Brunt et al. 
2017).   
 Ring-substituted derivatives of 2-AI, such as 5-methoxy-2-aminoindan (5-MeO-AI, 
MEAI), 5-methoxy-6-methyl-2-aminoindan (MMAI), and 5,6-methylenedioxy-2-aminoindan 
(MDAI), have also been sold as designer drugs (Figure 1).  Encounters with MDAI were 
reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2010 
(EMCDDA 2011).  MDAI and MMAI were synthesized by Nichols et al. as potentially non-
neurotoxic entactogens (Nichols et al. 1990; Johnson et al. 1991b).  Both of these substances 
produce MDMA-like behavioral effects in rats (Nichols et al. 1990; Johnson et al. 1991b; Gatch 
et al. 2016) and increase 5-HT release with some selectivity vs. NE and DA (Johnson et al. 
1991a).  Use of MDAI reportedly induces euphoria and feelings of empathy, with 150-200 mg 
p.o. being a typical recreational dose (Corkery et al. 2013).  The third ring-substituted 
compound, 5-MeO-AI, appears to have been first synthesized in 1956 (Richter and Schenck 
1956) and has been proposed as a potential alcohol substitute (Golan 2016; Shimshoni et al. 
2017; Shimshoni et al. 2018).  5-MeO-AI reportedly produces mild psychoactive effects and 
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euphoria in recreational users (Slezak 2015).  5-MeO-AI is the active ingredient in a product 
called PaceDrink, which is marketed online as an alcohol-like intoxicant.  
 The goal of the present investigation was to assess the pharmacological properties of 2-
AI derivatives.  2-AI, MMAI, and MDAI reportedly act as substrate-type monoamine releasers 
(Simmler et al. 2014b; Eshleman et al. 2017) but full dose-response data for releasing activity 
(i.e., EC50 values) are only available for the latter compound.  Furthermore, much of what is 
known about the monoamine-releasing effects of aminoindans is based on assays conducted in 
non-neuronal cells overexpressing transporter proteins, which tend to underestimate the potency 
of substrate-type releasers by an order of magnitude or more compared to native tissues.  In 
studies of HEK293 (HEK) cells expressing DAT, (+)-methamphetamine released preloaded 
[3H]DA with EC50 = 435 nM (Eshleman et al. 2017) or EC50 = 1.56 µM (Simmler et al. 2013).  
By contrast, in rat brain synaptosomes, (+)-methamphetamine induced [3H]substrate efflux 
through DAT with EC50 values ranging from 8.5 nM to 28.0 nM (Rothman et al. 2001; Nagai et 
al. 2007; Baumann et al. 2012).  Although uptake assays have been used to assess interactions 
between aminoindans and monoamine transporters (Johnson et al. 1991a), those assays also tend 
to underestimate the potency of substrate releasers (Bhat et al. 2017).  In the present studies, the 
monoamine-releasing properties of 2-AI, 5-MeO-AI, MMAI, and MDAI were compared using in 
vitro release assays for DAT, NET, and SERT in rat brain synaptosomes.  In addition to their 
transporter interactions, aminoindans also bind to monoamine receptors (Marona-Lewicka and 
Nichols 1994; Iversen et al. 2013; Simmler et al. 2014b).  Existing binding studies with 2-AI, 
MMAI and MDAI, however, have only focused on a small subset of 5-HT, DA, and NE receptor 
subtypes.  Therefore, comprehensive binding studies were performed to assess the affinity of 
aminoindans at 5-HT, DA, and NE receptor subtypes.  The aminoindans were found to act as 
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substrate-type monoamine releasers with differing patterns of selectivity for SERT, DAT, and 
NET.  Consistent with previous reports indicating that certain 2-aminoindan derivatives bind to 
α2-adrenoceptors (Iversen et al. 2013; Simmler et al. 2014b), 2-AI, 5-MeO-AI, MMAI and 
MDAI had moderate to high affinity for α2-adrenoceptor subtypes. 
 
 
2.  MATERIALS AND METHODS 
 
2.1.  Animals 
 
 Male Sprague-Dawley rats (300-400 g, Envigo, Frederick, MD, USA) were housed 2 per 
cage and maintained on a 12 h light-dark cycle.  Food and water were provided ad libitum.  
Animal use procedures were conducted in accordance with the NIH Guide for the Care and Use 
of Laboratory Animals, and the Animal Care and Use Committee of the Intramural Research 
Program of the National Institute on Drug Abuse (Baltimore, MD, USA).   
 
2.2.  Drugs 
 
 2-Aminoindan (2-AI) hydrochloride, 5-methoxy-6-methyl-2-aminoindan (MMAI) 
hydrochloride, and 5,6-methylenedioxy-2-aminoindan (MDAI) hydrochloride were obtained 
from Cayman Chemical (Ann Arbor, MI, USA).  5-Methoxy-2-aminoindan (2-MeO-AI) 
hydrochloride was obtained from Key Organics Ltd (Cornwall, UK). 
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2.3.  Transporter Release Assays 
 
 Rats were euthanized by CO2 narcosis and the brains were removed and processed to 
yield synaptosomes.  Briefly, caudate tissue (for DAT assays) or whole brain minus cerebellum 
and caudate (for NET and SERT assays) was homogenized in ice-cold 10% sucrose containing 1 
µM reserpine.  After 12 strokes with a Potter-Elvehjem homogenizer, the homogenates were 
centrifuged at 1,000 × g at 4°C for 10 min and the supernatants (i.e., synaptosomal preparations) 
were retained on ice.  Transporter assays were carried out as described previously (Baumann et 
al. 2013; Solis et al. 2017).  For the release assays, 9 nM [3H]1-methyl-4-phenylpyridinium 
([3H]MPP+) was used as the radiolabeled substrate for DAT and NET, whereas 5 nM [3H]5-HT 
was used as the radiolabeled substrate for SERT.  All buffers used in the release assays contained 
1 µM reserpine to block vesicular uptake of substrates.  The selectivity of release assays was 
optimized for a single transporter by including unlabeled blockers to prevent the uptake of 
[3H]MPP+ or [3H]5-HT by competing transporters.  Desipramine (100 nM) and citalopram (100 
nM) were added to the buffer for DAT release experiments.  Citalopram (100 nM) and GBR 
12935 (50 nM) were added to the buffer for NET release experiments.  GBR 12935 (50 nM) and 
nomifensine (100 nM) were added to the buffer for SERT release experiments.  Synaptosomes 
were preloaded with radiolabelled substrate in Krebs-phosphate buffer for 1 h (steady state).  
Release assays were initiated by adding 850 µL of preloaded synaptosomes to 150 µL of test 
drug.  The release assays were terminated by vacuum filtration and retained radioactivity was 
quantified by scintillation counting.  Effects of test drugs on release were expressed as % 
maximum release, with maximum release (Emax) defined as the release produced by tyramine at 
doses that evoke the efflux of all ‘releasable’ tritium by synaptosomes (10 µM tyramine for DAT 
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and NET assay conditions, and 100 µM tyramine for SERT assay conditions; Rothman et al. 
2001).  Effects of test drugs on release were analyzed by nonlinear regression using GraphPad 
Prism 6 (GraphPad Software, San Diego, CA) to calculate EC50 values. 
 
2.4.  Radioligand Binding Assays 
 
 A screening at 29 receptor and transporter binding sites was performed by the NIMH 
Psychoactive Drug Screening Program (NIMH PDSP). Most of these screenings were performed 
with cloned human receptors; exceptions are listed in Table 2. Test compounds were dissolved in 
DMSO and were tested at 10 µM in competition assays against radioactive probe compounds. 
Sites exhibiting > 50% inhibition at 10 µM were tested in secondary assays at the identified 
receptor or transporter using 12 concentrations of the drug (0.1 nM – 10 µM), measured in 
triplicate, to generate competition binding isotherms. Ki values were obtained from nonlinear 
regression of these binding isotherms from best-fit IC50 values using the Cheng-Prusoff equation 
(Cheng and Prusoff 1973). The radioligands used were as follows: [3H]8-OH-DPAT (5-HT1A), 
[3H]GR125743 (5-HT1B/1D), [3H]ketanserin (5-HT2A), [3H]LSD (5-HT2B/5A/6/7), [3H]mesulergine 
(5-HT2C), [3H]citalopram (serotonin transporter), [3H]prazosin (α1A/1B/1D), [3H]rauwolscine 
(α2A/2B/2C), [125I]pindolol (β1), [3H]CGP12177 (β2, β3), [3H]nisoxetine (norepinephrine 
transporter), [3H]SCH23390 (D1, D5), [3H]N-methylspiperone (D2/3/4), [3H]WIN35428 
(dopamine transporter), [3H](+)-pentazocine (σ1), and [3H]DTG (σ2). For more information, see: 
Besnard et al. (2012). The experimental protocols are available from the NIMH PDSP website 
(Roth 2013). 
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3.  RESULTS 
 
3.1.  Effects on Monoamine Release 
 
 The aminoindans displayed efficacious releasing activity at DAT, NET, and SERT.  As 
depicted in Figure 2, 2-AI, 5-MeO-AI, MMAI, and MDAI produced a dose-dependent increase 
in the efflux of [3H]MPP+ and [3H]5-HT from preloaded synaptosomes.  Table 1 summarizes the 
dose-response data for the 2-aminoindans, including the EC50 values and selectivity ratios for 
each compound.  The unsubstituted parent compound 2-AI is a catecholamine-selective drug, 
with potent releasing actions at NET (EC50 = 86 nM) and DAT (EC50 = 439 nM) but not at SERT 
(EC50 > 10,000 nM).  With regard to selectivity ratios, 2-AI displayed a DAT/NET ratio of 0.20 
and a DAT/SERT ratio of > 22, confirming its selectivity toward catecholamine transporters.  
For comparative purposes, (+)-amphetamine showed a DAT/NET ratio of 0.29 and a DAT/SERT 
ratio of 71 in previous synaptosomal release experiments (Rothman et al. 2001).  Ring-
substitution markedly increases potency towards SERT, creating agents that are at least 10-fold 
selective for SERT over DAT.  MDAI is equipotent at SERT and NET, with 10-fold weaker 
effects at DAT, yielding a DAT/SERT ratio of 0.08.  Compared to MDAI, 5-MeO-AI had a 
lower DAT/SERT ratio (0.05), and was moderately selective for SERT vs. NET and DAT.  
MMAI is a potent and selective 5-HT releaser, displaying a DAT/SERT ratio of > 0.003.   
 
3.2.  Binding Affinities 
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 The binding affinities of the aminoindans for 29 receptors and binding sites are shown in 
Table 2.  All compounds bound to α2 adrenoceptors with submicromolar or micromolar affinities 
but lacked appreciable affinity for α1- and β-adrenergic receptors (< 50% displacement at 10 
µM).  2-AI had high affinity for α2A (Ki = 134 nM), α2B (Ki = 211 nM), and α2C (Ki = 41 nM) 
receptors.  Compared to 2-AI, 5-MeO-AI and MMAI had 5-fold lower affinity for α2A and α2B 
and 30-fold lower affinity for α2C, indicating that 5-methoxy substitution has a detrimental effect 
on α2 binding.  Similar reductions in affinity for α2 adrenoceptor subtypes occurred with MDAI.  
2-AI and MDAI lacked affinity for 5-HT receptors (< 50% displacement at 10 µM), whereas the 
5-methoxy-substituted compounds 5-MeO-AI and MMAI had moderate affinity for 5-HT1A and 
5-HT2B receptors.  The presence of a 6-methyl-substituent apparently facilitates binding to 5-
HT1B, 5-HT1D, and 5-HT7 receptors because MMAI had moderate affinity for those sites whereas 
5-MeO-AI had little or no affinity. With the exception of MDAI, which bound to SERT with a Ki 
of 4,822 nM, the aminoindans displayed low potency for inhibiting binding of high-affinity 
radioligands to or monoamine transporters (< 50% displacement at 10 µM).  None of the 
compounds were active at dopaminergic receptors or σ binding sites.   
 
4.  DISCUSSION 
 
 All of the aminoindans tested stimulate monoamine efflux via transporters, albeit with 
varying degrees of selectivity for DAT, NET, and SERT.  Based on the transporter data, the 
parent compound 2-AI is a selective substrate for NET and DAT, similar to (+)-amphetamine 
(Rothman et al. 2001).  Ring substitution on 2-AI increased the potency of SERT-mediated 
release while reducing potency at DAT and NET.  MDAI is a moderately selective releaser via 
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SERT and NET, with 10-fold weaker effects on DAT, meaning it increases 5-HT release in a 
manner similar to MDMA but has somewhat weaker effects on DA release (cf., Rothman et al. 
2001).  5-MeO-AI exhibited some selectivity for SERT-mediated release, having 6-fold lower 
potency at NET and 20-fold lower potency at DAT.  Consistent with previous reports (Johnson et 
al. 1991a; Marona-Lewicka and Nichols 1994; Luethi et al. 2017), MMAI is highly selective 
SERT releaser, with 100-fold lower potency at NET and DAT.  In addition to their effects on 
monoamine release, the aminoindans had relatively high affinity for α2-adrenoceptor subtypes.  
The 5-methoxy substituted compounds (5-MeO-AI and MMAI) also bind to 5-HT1A and 5-HT2B 
receptors with moderate affinity. 
 The release data for the aminoindans correlate well with data from previous studies.  
Liechti and colleagues examined the effects of 2-AI, MDAI, and MMAI on monoamine release 
from HEK cells expressing cloned transporters (Simmler et al. 2014b; Luethi et al. 2017).  At 
100 µM, 2-AI induced the release of preloaded [3H]DA and [3H]NE but not [3H]5-HT, MDAI 
released [3H]5-HT and [3H]NE whereas [3H]DA was not affected, and MMAI released [3H]5-HT 
selectively.  Although full dose-effect curves for [3H]transmitter release were not reported by 
Liechti et al., we observed the same qualitative pattern of activity with 2-aminoindans in our 
synaptosomal release assays.  Thus, data from human transporters expressed in non-neuronal 
cells agree with our data from rat transporters in native tissue preparations. According to another 
group (Eshleman et al. 2017), MDAI released preloaded [3H]NE (EC50 = 0.57 µM), [3H]5-HT 
(EC50 = 2.9 µM), and [3H]DA (EC50 = 24 µM) from HEK cells expressing cloned transporters.  
These data confirm the ~10-fold selectivity of MDAI for 5-HT vs. DA release.  In comparison, 
MDAI had 5- to 25-fold higher potency in our release assays, which is not surprising because 
HEK cells may not express critical elements of the protein machinery found in intact neurons 
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that are implicated in the monoamine-releasing effects of amphetamines.  Finally, Johnson et al. 
(1991a) used synaptosomal uptake assays to characterize the interaction of MDAI and MMAI 
with DAT, NET and SERT.  There was a narrow margin of separation between the effects of 
MDAI on [3H]5-HT uptake (IC50 = 512 nM) and [3H]NE uptake (IC50 = 1426 nM), whereas 
[3H]DA uptake was inhibited with 10-fold lower potency (IC50 = 5,920 nM).  Conversely, 
MMAI inhibited the uptake of [3H]5-HT with an IC50 of 212 nM, which was 55-fold lower than 
the concentration required to inhibit [3H]NE uptake (IC50 = 11,618 nM) and 93-fold lower than 
the concentration required to inhibit [3H]DA uptake (IC50 = 19,793 nM).  These data are 
consistent with the selectivity profile of MDAI and MMAI in our release assays. 
 Although we found little evidence of binding to DAT, NET, and SERT (in most cases 
there was < 50% displacement at 10 µM), this does not exclude the possibility that the 
aminoindans act as monoamine reuptake inhibitors.  Indeed, as was noted above, MMAI inhibits 
synaptosomal [3H]5-HT uptake at submicromolar concentrations (Johnson et al. 1991a).  For 
substrate releasers, the concentration required to displace radioligand binding to the transporter is 
often 10- to 100-fold higher than the concentration required to inhibit neurotransmitter uptake 
(Simmler et al. 2013; Simmler et al. 2014a; Eshleman et al. 2017).  For example, 
methamphetamine inhibits [3H]DA uptake with about 70-fold higher potency than it displaces 
[125I]RTI-55 binding to hDAT (IC50 = 0.0667 µM vs. Ki = 4.58 µM, respectively) (Eshleman et 
al. 2017).  These potency differences likely occur because radiolabeled inhibitors stabilize 
monoamine transporters in the outward-facing conformation whereas substrate releasers shift 
transporters to the inward-facing conformation (Erreger et al. 2008; Sandtner et al. 2016; Bhat et 
al. 2017).   
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 The release assays used in these experiments are based on the efflux of preloaded 
synaptosomal [3H]neurotransmitter via a transporter-mediated exchange process thought to 
involve the reversal of normal transporter flux (i.e., “reverse” transport) (Rudnick and Clark 
1993; Rothman and Baumann 2006b).  Substrate-type drugs will deplete [3H]neurotransmitter 
from synaptosomes via this reverse transport mechanism in a concentration-dependent manner.  
Synaptosomes are sealed vesicle-filled nerve endings with their plasma membrane leaflets 
oriented in a manner akin to neurons in vivo (Gray and Whittaker 1962; Wilhelm et al. 2014). In 
contrast to assay systems involving non-neuronal cells transfected with transporter proteins, 
synaptosomes possess all of the cellular machinery necessary for neurotransmitter synthesis, 
release, metabolism and reuptake.  Synaptosomes, however, do not model all of the effects of 
amphetamine-type agents because the use of reserpine removes any contribution of the vesicular 
monoamine transporter VMAT2 (SLC18A2) to the release process.  In addition to acting as a 
substrate for plasma membrane monoamine transporters, amphetamine also binds to VMAT, 
resulting in the redistribution of monoamines from vesicular stores to the cytoplasm (Sulzer et al. 
1995; Partilla et al. 2006; Freyberg et al. 2016).  Although transporter substrates can induce 
monoamine release in the absence of VMAT binding (Fon et al. 1997), it is important to 
recognize that 2-aminoindans may have effects in intact nerve terminals that are not fully 
replicated in synaptosomes.  Follow-up studies will be conducted to evaluate whether 2-
aminoindans are capable of interacting with VMAT.  In addition to members of the solute carrier 
(SLC) family, several other presynaptic components are thought to contribute to the action of 
substrate releasers, for example monoamine oxidase (MAO), the trace amine-associated receptor 
TAAR1, and protein kinases (Sulzer et al. 2005; Sitte and Freissmuth 2015).  It is important to 
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determine how those targets contribute to the effects of aminoindans and other monoamine-
releasing compounds. 
 The subjective effects and abuse potential of substrate-type monoamine releasers vary 
depending on their transporter selectivity.  Self-administration of monoamine releasers is driven 
primarily by DA efflux in the mesolimbic pathway (Wise 1996; Pierce and Kumaresan 2006) 
whereas the psychostimulant effects of amphetamines are mediated by their effects on NE 
release (Rothman et al. 2001; Sofuoglu et al. 2009; Hysek et al. 2011).  By contrast, 5-HT release 
appears to produce MDMA-like entactogenic effects.  The entactogenic effects of MDMA are 
blocked by pretreatment with the selective SERT inhibitors paroxetine and fluoxetine (Liechti et 
al. 2000; Farre et al. 2007; Tancer and Johanson 2007), which prevent carrier-mediated release 
of 5-HT without limiting access to catecholamine transporters or postsynaptic receptors.  The 
relative catecholaminergic-serotonergic effects of monoamine releasing agents appear to be an 
important determinant of their abuse potential; catecholamine-selective drugs have the highest 
reinforcing potency in self-administration and ICSS studies, with stimulant and reinforcing 
effects declining as 5-HT releasing potency increases (Wee et al. 2005; Rothman and Baumann 
2006a; Baumann et al. 2011; Bauer et al. 2013).   Consistent with its reported amphetamine-like 
psychoactive effects in humans, 2-AI is a catecholamine-selective releaser, with minimal effect 
on 5-HT release.  Based on the transporter data, MDAI and 5-MeO-AI may produce MDMA-like 
entactogenic and sympathomimetic effects but are likely to have less abuse liability than the 
latter agent.  The effect of MMAI on monoamine release is reminiscent of m-
trifluoromethylphenylpiperazine (TFMPP) and fenfluramine, which are highly selective for 5-HT 
release relative to DA and NE (Rothman et al. 2003; Baumann et al. 2005).  Selective 5-HT 
releasers such as TFMPP and fenfluramine lack euphoric effects in humans and can produce 
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dysphoria at higher doses (Griffith et al. 1975; Foltin and Fischman 1991; Jan et al. 2010); 
therefore, MMAI may have unpleasant effects, limiting its abuse liability.  Indeed, whereas 
MDMA (Bilsky et al. 1990; Marona-Lewicka et al. 1996) and MDAI (Gatch et al. 2016) produce 
conditioned place preference in rats, MMAI reportedly induces conditioned place aversion 
(Marona-Lewicka et al. 1996). 
 The effects of the aminoindans on monoamine release are consistent with their stimulus 
properties in rodents.  2-AI fully substituted for (+)-amphetamine, demonstrating that it produces 
an amphetamine-like interoceptive stimulus cue (Glennon et al. 1984).  Another study reported 
only partial substitution by 2-AI in (+)-amphetamine-trained rats (Oberlender and Nichols, 
1991); however, the range of 2-AI doses tested was limited by rate-depressant effects, and it 
cannot be excluded that 2-AI would have produced full substitution at higher doses.  The 
discriminative stimulus cue evoked by MMAI appears to be mediated by 5-HT efflux; 5-HT 
releasers such as MDMA, S-(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (S-(+)-
MBDB), and (+)-fenfluramine fully substituted for MMAI, whereas (+)-amphetamine and 
cocaine did not substitute, and MMAI discrimination was antagonized by 5-HT uptake inhibitors 
as well as by depletion of endogenous 5-HT (Marona-Lewicka and Nichols 1994,1998).  
Likewise, MMAI fully substituted in rats trained to discriminate the 5-HT releasing drugs 
MDMA and S-(+)-MBDB, but did not substitute in (+)-amphetamine-trained rats (Johnson et al. 
1991b).  MDAI substituted for MDMA and S-(+)-MBDB (Nichols et al. 1990; Oberlender and 
Nichols 1990; Malmusi et al. 1996; Gatch et al. 2016), which is consistent with its effects on 5-
HT efflux.  Although MDAI did not substitute for (+)-amphetamine (Oberlender and Nichols 
1991), it did produce full substitution in cocaine-trained rats and 75% drug-appropriate 
responding in (+)-methamphetamine-trained rats (Gatch et al. 2016); therefore, there may be 
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some overlap between the stimulus effects of MDAI and psychostimulants, as is the case with 
MDMA (Schechter 1986; Glennon 1989; Gatch et al. 2009).  Data regarding the stimulus 
properties of 5-MeO-AI have not appeared in the literature. 
 All of the aminoindans tested in this study have moderate to high affinity for α2-
adrenoceptor subtypes.  Consistent with our data, previous studies reported that 2-AI, MDAI, 
MMAI, and 5-iodo-2-aminoindan (5-IAI) bind to α2 receptors with affinity in the submicromolar 
or low micromolar range (Marona-Lewicka and Nichols 1994; Iversen et al. 2013; Simmler et al. 
2014b; Luethi et al. 2017).  Activity in the series peaked with the unsubstituted compound 2-AI, 
which bound to the three subtypes with nanomolar affinity (α2A Ki = 134 nM, α2B Ki = 211 nM, 
and α2C Ki = 41 nM).  In comparison, (+)-amphetamine and (+)-methamphetamine have lower 
affinity for cloned human α2-adrenoceptors labeled with [3H]rauwolscine (Ki values of 2.8 µM 
and 6.1 µM, respectively; Simmler et al. 2013).  MDMA also binds to α2-adrenoceptors in 
frontal cortex homogenates with micromolar affinity (Ki = 3.2 µM vs. [3H]p-aminoclonidine) 
(Battaglia et al. 1988).  Although aminoindans have higher affinity for α2-adrenoceptor subtypes 
compared to amphetamines, the significance of these interactions to the behavioral 
pharmacology of these compounds is unclear.   
 The interaction of aminoindans with 5-HT2B receptors is noteworthy.  It is apparent that 
aromatic ring substitution enhances the binding of aminoindans to 5-HT2B receptor sites based on 
our finding that 5-MeO-AI and MMAI have higher affinity than 2-AI.  Similarly, according to 
Iversen et al. (2013), 5-iodo-2-aminoindan (5-IAI) binds to the 5-HT2B receptor with high 
affinity (Ki = 70 nM vs. [3H]LSD).  Although MDAI also displays ring-substitution at the 5 
position, it was shown herein and in previous studies (Iversen et al. 2013) to have negligible 
affinity for the 5-HT2B receptor (< 50% displacement at 10 µM).  5-HT2B activation has been 
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linked to valvular heart disease induced by fenfluramine and ergot alkaloids such as 
methysergide, pergolide, cabergoline, and ergotamine (Fitzgerald et al. 2000; Rothman et al. 
2000; Roth 2007; Huang et al. 2009).  Additionally, the 5-HT2B receptor may be responsible for 
the primary pulmonary hypertension observed in patients treated with fenfluramine or the 
anorectic aminorex (Rothman et al. 1999; Launay et al. 2002).  Our study did not determine 
whether 5-MeO-AI and MMAI act as agonists or antagonists at the 5-HT2B receptor but the fact 
that the drugs bind to this site raises the possibility that they may present some risk for cardiac 
and pulmonary toxicities.  Indeed, abuse of substances with 5-HT2B agonist activity has been 
linked to cardiac valvulopathy and pulmonary hypertension.  MDMA (Ki = 500 nM vs. 
[3H]LSD) and its N-demethylated metabolite MDA (Ki = 100 nM vs. [3H]LSD) act as 5-HT2B 
agonists (Setola et al. 2003); one study found an elevated incidence of valvular heart disease in a 
Belgian group of MDMA users (Droogmans et al. 2007).  Abuse of 4-methylaminorex (McN-
822, “U4Euh”) has been associated with the development of pulmonary hypertension in case 
reports (Gaine et al. 2000). 
 In addition to their effects on cardiovascular physiology, 5-HT2B receptors have also been 
shown to modulate the effects of psychostimulant and entactogenic drugs.  5-HT2B receptor 
activation reportedly plays a permissive role in the activity of 5-HT neurons in the dorsal raphe 
nucleus (Belmer et al. 2018).  Indeed, selective 5-HT2B antagonists block MDMA-induced 
release of 5-HT and DA and inhibit the hyperlocomotor and reinforcing effects of MDMA in 
mice (Doly et al. 2008; Doly et al. 2009).  According to another report, the ability of 
amphetamine to increase nucleus accumbens DA outflow and locomotor activity is significantly 
attenuated in animals pretreated with the selective 5-HT2B antagonist LY 266097 (Auclair et al. 
2010).  Additionally, 5-HT2B receptor gene variants have been linked to drug abuse (Lin et al. 
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2004; Tikkanen et al. 2015), which supports a potential role for this receptor in drug-induced 
rewarding effects.  It is tempting to speculate that effects of 5-MeO-AI and MMAI on 
serotonergic and dopaminergic neurotransmission may be modulated by their interaction with the 
5-HT2B receptor.   
 In summary, aminoindans target plasma membrane monoamine transporters.  The 
unsubstituted parent compound 2-AI increases DA and NE release in a manner analogous to (+)-
amphetamine.  5-MeO-AI and MDAI, by contrast, produce MDMA-like effects on 5-HT and NE 
release, although they have less of an effect on DA release in comparison to the latter drug.  
MMAI increases 5-HT release selectively.  Although these results are consistent with existing 
evidence indicating that 2-AI and MDAI have some abuse liability, self-administration studies 
are ultimately necessary to assess whether these substances produce reinforcing effects.  It is 
especially important to perform these studies with 5-MeO-AI because it is the active ingredient 
in a product (“Pace”) marketed online as a replacement for alcohol.   Although some preliminary 
pharmacological data have been reported for 5-MeO-AI (Shimshoni et al. 2018), as far as we are 
aware the present studies are the first detailed investigation of this emerging drug.  Additional 
studies with 5-MeO-AI are warranted given its ability to interact with monoamine transporters 
and 5-HT2B receptors. 
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Table 1.  Effects of 2-aminoindan analogues on the release of tritiated substrates via DAT, 
NET or SERT in rat brain synaptosomes 
Drug DAT-mediated 
release 
EC50 (nM) 
(Emax) 
NET-mediated 
release 
EC50 (nM) 
(Emax) 
SERT-mediated 
release 
EC50 (nM) 
(Emax) 
DAT/NET 
ratioa 
DAT/SERT 
ratiob 
2-AI 
 
439 ± 38 
(106%) 
86 ± 13 
(95%) 
>10,000 
n.d. 
0.20 >22.78 
5-MeO-AI 
 
2,646 ± 565 
(117%) 
861 ± 118 
(101%) 
134 ± 13 
(104%) 
0.33 0.05 
MMAI 
 
>10,000 
n.d. 
3,101 ± 728 
(105%) 
31 ± 5 
(99%) 
>0.31 >0.003 
MDAI 
 
1,334 ± 226 
(113%) 
117 ± 17 
(99%) 
114 ± 15 
(102%) 
0.09 0.08 
 
Data are mean ± S.D. for 3 independent experiments performed in triplicate 
aDAT/NET ratio = (DAT EC50)-1 ÷ (NET EC50)-1; a higher value indicates greater DAT 
selectivity   
bDAT/SERT ratio = (DAT EC50)-1 ÷ (SERT EC50)-1; a higher value indicates greater DAT 
selectivity 
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Table 2.  Summary of radioligand binding data for the 2-aminoindan analogues  
aThe experiments were performed using cloned human receptors unless otherwise specified.   
bData represent mean and S.D. from 3–4 independent experiments performed in triplicate (the number of 
experiments is indicated in parentheses). 
c< 50% displacement when tested at 10 µM in the primary binding assay. 
dThe experiment was performed using tissues or cells natively expressing the receptor.
   2-AI 5-MeO-AI MMAI MDAI 
Receptor Speciesa Radioligand Ki (nM)b Ki (nM) Ki (nM) Ki (nM) 
5-HT1A Human [3H]8-OH-DPAT > 10,000c 2,503 ± 1,867 (3) 1,077 ± 590 (4) > 10,000 
5-HT1B Human [3H]GR125743 > 10,000 > 10,000 2,777 ± 326 (3) > 10,000 
5-HT1D Human [3H]GR125743 > 10,000 > 10,000 2,559 ± 980 (3)  > 10,000 
5-HT1E Human [3H]5-HT > 10,000 > 10,000 > 10,000 > 10,000 
5-HT2A Human [3H]ketanserin > 10,000 > 10,000 > 10,000 > 10,000 
5-HT2B Human [3H]LSD > 10,000 4,793 ± 2,994 (3) 902 ± 445 (3) > 10,000 
5-HT2C Human [3H]mesulergine > 10,000 > 10,000 > 10,000 > 10,000 
5-HT5A Human [3H]LSD > 10,000 > 10,000 > 10,000 > 10,000 
5-HT6 Human [3H]LSD > 10,000 > 10,000 > 10,000 > 10,000 
5-HT7 Human [3H]LSD > 10,000 > 10,000 1,008 ± 262 (3)  > 10,000 
α1A Human [3H]prazosin > 10,000 > 10,000 > 10,000 > 10,000 
α1B Human [3H]prazosin > 10,000 > 10,000 > 10,000 > 10,000 
α1D Human [3H]prazosin > 10,000 > 10,000 > 10,000 > 10,000 
α2A Human [3H]rauwolscine 134 ± 31 (3) 751 ± 338 (3)  724 ± 477 (4)  322 ± 114 (3) 
α2B Human [3H]rauwolscine 211 ± 81 (3) 1,555 ± 757 (3)  1,229 ± 483 (3) 1,121 ± 411 (3) 
α2C Human [3H]rauwolscine 41 ± 26 (4) 1,224 ± 238 (3) 1,380 ± 769 (4) 363 ± 219 (4) 
β1 Human heartd [125I]pindolol > 10,000 > 10,000 > 10,000 > 10,000 
β2 Human [3H]CGP12177 > 10,000 > 10,000 > 10,000 > 10,000 
β3 Human [3H]CGP12177 > 10,000 > 10,000 > 10,000 > 10,000 
D1 Human [3H]SCH23390 > 10,000 > 10,000 > 10,000 > 10,000 
D2 Human [3H]NMSP > 10,000 > 10,000 > 10,000 > 10,000 
D3 Human [3H]NMSP > 10,000 > 10,000 > 10,000 > 10,000 
D4 Human [3H]NMSP > 10,000 > 10,000 > 10,000 > 10,000 
D5 Human [3H]SCH23390 > 10,000 > 10,000 > 10,000 > 10,000 
DAT Human [3H]WIN35,428 > 10,000 > 10,000 > 10,000 > 10,000 
NET Human [3H]nisoxetine > 10,000 > 10,000 > 10,000 > 10,000 
SERT Human [3H]citalopram > 10,000 > 10,000 4,822 ± 2,500 (3) > 10,000 
σ1 Rat braind [3H](+)pentazocine > 10,000 > 10,000 > 10,000 > 10,000 
σ2 Rat PC12 cellsd [3H]DTG > 10,000 > 10,000 > 10,000 > 10,000 
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FIGURE CAPTIONS 
 
 
 
 
Figure 1.  Chemical structures of aminoindans and related drugs.  Abbreviations: 2-AI, 2-
aminoindan; MDAI, 5,6-methylenedioxy-2-aminoindan; MDMA, 3,4-
methylenedioxymethamphetamine; 5-MeO-AI, 5-methoxy-2-aminoindan; MMAI, 5-methoxy-6-
methyl-2-aminoindan.  
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Figure 2.  Dose-response effects of aminoindans on the release of [3H]MPP+ and [3H]5-HT from 
rat brain synaptosomes in vitro, under conditions optimized for NET, DAT, and SERT.  Dose-
response curves were constructed by incubating various concentrations of each test drug with 
synaptosomes that had been preloaded with tritiated substrate ([3H]MPP+ for NET and DAT, 
[3H]5-HT for SERT).  Test drugs were 2-aminoindan (2-AI), 5-methoxy-2-aminoindan (5-MeO-
AI), 5-methoxy-6-methyl-2-aminoindan (MMAI), and 5,6-methylenedioxy-2-aminoindan 
(MDAI).  Data are mean±S.D. for 3 independent experiments performed in triplicate. 
